enGene Appoints Robert Hariri CEO, Mary Ann Gray Departs Board
Ticker: ENGNW · Form: 8-K · Filed: Jul 24, 2024 · CIK: 1980845
Sentiment: neutral
Topics: leadership-change, management-appointment, board-of-directors
TL;DR
Hariri is CEO now, Gray is out. Big changes at enGene.
AI Summary
On July 22, 2024, enGene Holdings Inc. announced the appointment of Dr. Robert L. Hariri as Chief Executive Officer and a member of the Board of Directors. Dr. Hariri, who previously served as Chief Medical Officer, will lead the company's strategic direction and operational execution. The company also announced the departure of Dr. Mary Ann Gray from the Board of Directors.
Why It Matters
The appointment of a new CEO often signals a shift in company strategy or operational focus, which could impact future performance and investor outlook.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, impacting the company's stability and performance.
Key Players & Entities
- enGene Holdings Inc. (company) — Registrant
- Robert L. Hariri (person) — Appointed CEO and Board Member
- Mary Ann Gray (person) — Departed Board Member
- July 22, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new CEO of enGene Holdings Inc.?
Dr. Robert L. Hariri has been appointed as the new Chief Executive Officer of enGene Holdings Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on July 22, 2024.
Who has departed from the Board of Directors of enGene Holdings Inc.?
Dr. Mary Ann Gray has departed from the Board of Directors of enGene Holdings Inc.
What other role did Robert L. Hariri hold prior to becoming CEO?
Prior to becoming CEO, Dr. Robert L. Hariri served as Chief Medical Officer.
What is the primary business of enGene Holdings Inc. according to the filing?
enGene Holdings Inc. is in the business of BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,976 words · 8 min read · ~7 pages · Grade level 10.9 · Accepted 2024-07-24 06:50:56
Key Financial Figures
- $11.50 — e Common Share, at an exercise price of $11.50 per Common Share ENGNW The Nasdaq S
- $700,000 — is entitled to an annual base salary of $700,000, to an annual 60% bonus opportunity (pr
- $8.81 — 2024 at an exercise price per share of $8.81. The stock option has a 10-year term an
- $390,000 — he Hanson Employment Agreement shall be $390,000, less applicable tax withholdings. The
- $25,000 — riod") in exchange for a monthly fee of $25,000 for the initial six-month Consulting Pe
- $500 — nitial six-month Consulting Period, and $500 per hour thereafter, provided that Mr.
Filing Documents
- d597787d8k.htm (8-K) — 41KB
- d597787dex101.htm (EX-10.1) — 69KB
- d597787dex102.htm (EX-10.2) — 6KB
- d597787dex991.htm (EX-99.1) — 11KB
- g597787g0724085501980.jpg (GRAPHIC) — 4KB
- 0001193125-24-183292.txt ( ) — 324KB
- engn-20240722.xsd (EX-101.SCH) — 3KB
- engn-20240722_def.xml (EX-101.DEF) — 14KB
- engn-20240722_lab.xml (EX-101.LAB) — 23KB
- engn-20240722_pre.xml (EX-101.PRE) — 15KB
- d597787d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Employment Agreement, dated July 22, 2024, by and between enGene USA, Inc. and Ronald H. W. Cooper.* 10.2 Amendment to Transition and Modification Agreement, dated July 23, 2024, by and between enGene USA, Inc. and Jason D. Hanson.* 99.1 Press Release of the Company dated July 24, 2024. 104 Cover Page Interactive Data File (Formatted as Inline XBRL) * Indicates a management contract or compensatory plan or arrangement. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENGENE HOLDINGS INC. Date: July 24, 2024 By: /s/ Lee Giguere Name: Lee Giguere Title: Chief Legal Officer